Orphenadrine Citrate - CAS 4682-36-4
Catalog number:
4682-36-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H23NO.C6H8O7
Molecular Weight:
461.5
COA:
Inquire
Targets:
NMDA Receptor
Description:
Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Multidrug toxicity involving sumatriptan.
Knittel JL1, Vorce SP2, Levine B2, Hughes RL2, Bosy TZ2. J Anal Toxicol. 2015 Jan-Feb;39(1):75-9. doi: 10.1093/jat/bku120. Epub 2014 Oct 16.
A multidrug fatality involving sumatriptan is reported. Sumatriptan is a tryptamine derivative that acts at 5-HT(1B/1D) receptors and is used for the treatment of migraines. The decedent was a 21-year-old white female found dead in bed by her spouse. No signs of physical trauma were observed and a large number of prescription medications were discovered at the scene. Toxicological analysis of the central blood revealed sumatriptan at a concentration of 1.03 mg/L. Following therapeutic dosing guidelines, sumatriptan concentrations do not exceed 0.095 mg/L. Sumatriptan was isolated by solid-phase extraction and analyzed using liquid chromatography-tandem mass spectrometry in multiple reaction monitoring mode. A tissue distribution study was completed with the following concentrations measured: 0.61 mg/L in femoral blood, 0.56 mg/L in iliac blood, 5.01 mg/L in urine, 0.51 mg/kg in liver, 3.66 mg/kg in kidney, 0.09 mg/kg in heart, 0.32 mg/kg in spleen, 0.
2.Nickel(0)-Catalyzed Enantio- and Diastereoselective Synthesis of Benzoxasiloles: Ligand-Controlled Switching from Inter- to Intramolecular Aryl-Transfer Process.
Kumar R, Hoshimoto Y, Yabuki H, Ohashi M, Ogoshi S1. J Am Chem Soc. 2015 Sep 16;137(36):11838-45. doi: 10.1021/jacs.5b07827. Epub 2015 Sep 3.
A highly enantioselective synthesis of 3-aryl-, vinyl-, and alkynyl-2,1-benzoxasiloles (up to 99.9% ee and 99% yield) was achieved via the sequential activation of an aldehyde and a silane by nickel(0). This strategy was applied to a simultaneous generation of carbon- and silicon-stereogenic centers with excellent selectivity (dr = 99:1) via diastereotopic aryl transfer. Initial mechanistic studies revealed the complete switching of an aryl-transfer process from an intermolecular (racemic synthesis in the presence of IPr) to an intramolecular (enantioselective synthesis using chiral NHC, L5) fashion. A plausible rationale for the switching of the aryl-transfer process is given by a preliminary DFT calculation, which suggests that the coordination of 1 to the nickel(0)/L5 fragment in an η(2)-arene:η(2)-aldehyde fashion would be a key to the intramolecular process, while the formation of the corresponding intermediate is not possible in the presence of IPr.
3.Status epilepticus caused by nefopam.
Park YS1, Kim YB1, Kim JM2. J Korean Neurosurg Soc. 2014 Nov;56(5):448-50. doi: 10.3340/jkns.2014.56.5.448. Epub 2014 Nov 30.
Nefopam, a centrally acting analgesic, has been used to control postoperative pain. Reported adverse effects are anticholinergic, cardiovascular or neuropsychiatric. Neurologic adverse reactions to nefopam are confusion, hallucinations, delirium and convulsions. There are several reports about fatal convulsive seizures, presumably related to nefopam. A 71-year-old man was admitted for surgery for a lumbar spinal stenosis. He was administered intravenous analgesics : ketorolac, tramadol, orphenadrine citrate and nefopam HCl. His back pain was so severe that he hardly slept for several days; he even needed morphine and pethidine. At 4 days of administration of intravenous analgesics, the patient suddenly started generalized tonic-clonic seizures for 15 seconds, and subsequently, status epilepticus; these were not responsive to phenytoin and midazolam. After 3 days of barbiturate coma therapy the seizures were controlled. Convulsive seizures related to nefopam appear as focal, generalized, myoclonic types, or status epilepticus, and are not dose-related manifestations.
4.Application of normalized spectra in resolving a challenging Orphenadrine and Paracetamol binary mixture.
Yehia AM1, Abd El-Rahman MK2. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Mar 5;138:21-30. doi: 10.1016/j.saa.2014.11.025. Epub 2014 Nov 15.
Normalized spectra have a great power in resolving spectral overlap of challenging Orphenadrine (ORP) and Paracetamol (PAR) binary mixture, four smart techniques utilizing the normalized spectra were used in this work, namely, amplitude modulation (AM), simultaneous area ratio subtraction (SARS), simultaneous derivative spectrophotometry (S(1)DD) and ratio H-point standard addition method (RHPSAM). In AM, peak amplitude at 221.6nm of the division spectra was measured for both ORP and PAR determination, while in SARS, concentration of ORP was determined using the area under the curve from 215nm to 222nm of the regenerated ORP zero order absorption spectra, in S(1)DD, concentration of ORP was determined using the peak amplitude at 224nm of the first derivative ratio spectra. PAR concentration was determined directly at 288nm in the division spectra obtained during the manipulation steps in the previous three methods. The last RHPSAM is a dual wavelength method in which two calibrations were plotted at 216nm and 226nm.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related NMDA Receptor Products


LY 257883
(CAS: 118183-22-5)

LY 257883, also known as PPPA, is a competitive NMDA receptor antagonist which displays moderate selectivity for NR2A-containing receptors. Ki values are 0.13μM...

CAS 125-71-3 dextromethorphan

dextromethorphan
(CAS: 125-71-3)

Dextromethorphan is an approved drug with sedative, dissociative, and stimulant properties. It is a cough suppressant in many over-the-counter cold and cough me...

CAS 130798-51-5 MDL 29951

MDL 29951
(CAS: 130798-51-5)

CAS 81338-23-0 D-AP7

D-AP7
(CAS: 81338-23-0)

D-AP7 is a selective NMDA receptor antagonist that inhibits the glutamate binding site and activation of NMDA receptor. It is the 8-Bromo-cGMP and the more acti...

CAS 137433-06-8 LY 235959

LY 235959
(CAS: 137433-06-8)

LY 235959 is a competitive N-Methyl-D-Aspartate Receptor antagonist originated by Eli Lilly. No development was reported for treatment of Movement disorders in ...

CAS 6700-34-1 Dextromethorphan hydrobromide hydrate

Dextromethorphan hydrobromide hydrate
(CAS: 6700-34-1)

Dextromethorphan, a dextratrorotatory morphinan, is a non-competitive, low affinity NMDA receptor antagonist.

Rapastinel
(CAS: 117928-94-6)

Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...

LaniceMine
(CAS: 153322-05-5)

Lanicemine, also know as AZD6765, has been to be a NMDA receptor antagonist that was once studiedd as a neuroprotective agent which was discontinued in 2007 and...

CAS 23210-58-4 Ifenprodil Tartrate

Ifenprodil Tartrate
(CAS: 23210-58-4)

Ifenprodil is an atypical noncompetitive antagonist at the NMDA receptor, it interacts with high affinity at a homogeneous population of NMDA receptors in neona...

CAS 253450-09-8 Besonprodil

Besonprodil
(CAS: 253450-09-8)

Besonprodil, a benzimidazolone bioisostere, is an NMDA antagonist that selective for the NR2B subunit.

CAS 768-94-5 Amantadine

Amantadine
(CAS: 768-94-5)

Amantadine is can be used as an antiviral and an antiparkinsonian drug. It is a NMDA receptor antagonist. Amantadine is also a useful building block in organic ...

CAS 59-47-2 Mephenesin

Mephenesin
(CAS: 59-47-2)

Mephenesin is an NMDA receptor antagonist, is a centrally acting muscle relaxant.

Apimostinel
(CAS: 1421866-48-9)

Apimostinel is a selective partial agonist of an allosteric site of the glycine site of the NMDA receptor complex under investigation by Naurex. Its mechanism o...

Ro 25-6981 Maleate
(CAS: 1312991-76-6)

The Maleate salt form of Ro 25-6981 which is a NMDA receptors blocker and has been found to exhibit neuroprotectant activity in vitro and in vivo. IC50: 9 nM.

Felbamate hydrate
(CAS: 1177501-39-1)

The hydrate of Felbamate which is an effective anticonvulsant agent. It was found to be clinically active for probably restraining the effectivity of NMDA.

CAS 127910-32-1 CGP 39551

CGP 39551
(CAS: 127910-32-1)

Cgp 39551 is a selective and competitive N-methyl-D-aspartate (NMDA) receptor antagonist originated by Novartis. Ki is 310 nM for inhibition of [3H]-CPP binding...

CAS 77086-22-7 (-)-MK-801 maleate

(-)-MK-801 maleate
(CAS: 77086-22-7)

(-)-MK-801 maleate is a potent, selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM that acts at the NMDA receptor-...

CAS 142326-59-8 L-701,324

L-701,324
(CAS: 142326-59-8)

L-701,324 is a selective antagonist at the glycine site of the NMDA glutamate receptor. L-701,324 shows a beneficial action in the animal model of parkinsonian ...

CGP 43487
(CAS: 146388-56-9)

CGP 43487 has been found to be a NMDA receptor antagonist and was once studied about its influenment of dopaminergic function as a supplement in the treatment o...

Radiprodil
(CAS: 496054-87-6)

Radiprodil is a orally active and selective NMDA NR2B antagonist with a potential therapeutic agent in treatment of neuropathic pain and possibly other chronic ...

Chemical Structure

CAS 4682-36-4 Orphenadrine Citrate

Quick Inquiry

Verification code

Featured Items